Grupo Ferrer Internacional S.A.

10 articles about Grupo Ferrer Internacional S.A.

• Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers

  7/3/2023

  The IMPAHCT event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologists from over 30 countries, consolidating the company’s commitment to the advancement of the research and treatment of pulmonary hypertension.

• Alexza Pharmaceuticals, Inc. Announces Grupo Ferrer Internacional S.A.'s Launch Of ADASUVE® (Staccato® Loxapine) In Spain Triggering A $1 Million Milestone Payment

  1/23/2014

• Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional S.A. Announce the Launch of ADASUVE&#0174 (Staccato&#0174 Loxapine) in Austria

  10/24/2013

• Grupo Ferrer Internacional S.A. Successfully Completes an Absorption, Tolerability and Safety Study in Juveniles as Young as Two Months of Age for Novel Antibacterial Compound Ozenoxacin

  10/5/2012

• Ferrer Submits IND for Arasertaconazole Nitrate, a Safe, Fast-Acting Topical Antifungal in Development for Vulvovaginal Candidiasis

  8/7/2012

• Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional S.A. Amend Adasuve(TM) Partnership

  3/8/2012

• Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional S.A. Establish $10 Million Partnership for the Commercialization of Adasuve(TM) (Staccato(R) Loxapine) in Europe and Latin America

  10/6/2011

• Vasogen and Grupo Ferrer Internacional S.A. Announce Initial Roll-out of Celacade

  12/17/2007

• Vasogen and Grupo Ferrer Internacional S.A. Form Collaboration to Commercialize Celacade(TM) in the European Union

  4/18/2007

• NicOx SA And Grupo Ferrer Internacional S.A. Select Candidate For Development In Dermatology Collaboration

  5/16/2006